Beijing Biostar Pharmaceuticals Co., Ltd. Class H (HK:2563) has released an update.
Beijing Biostar Pharmaceuticals has entered into a marketing service agreement with Baheal Zhihe, granting them exclusive rights to market and promote Utidelone Injection across mainland China. The agreement, spanning up to 15 years, includes milestone payments tied to research, development, and sales achievements. This strategic move positions Biostar to enhance its market presence and capitalize on Baheal Zhihe’s expertise in medical marketing.
For further insights into HK:2563 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
